Jesus Gonzalez-Cervera - Academia.edu (original) (raw)

Uploads

Papers by Jesus Gonzalez-Cervera

Alimentary Pharmacology & Therapeutics

SummaryBackgroundCow's milk protein is the main food trigger for eosinophilic oesophagitis (E... more SummaryBackgroundCow's milk protein is the main food trigger for eosinophilic oesophagitis (EoE) in children and adults and should be continuously avoided once identified as such.AimsTo evaluate tolerance of sterilised cow's milk (boiled instead of UHT processing) with regard to maintenance of EoE remission, health‐related quality of life (HRQoL), nutritional intake and allergic sensitisation in patients of all ages with milk‐triggered EoEMethodsWe prospectively recruited patients in whom cow's milk was demonstrated to trigger EoE after an empirical food elimination diet‐based study. They were given 200 ml of sterilised cow's milk twice daily for 8 weeks. Endoscopic assessment, peak eosinophil counts, oesophageal‐related symptoms, HRQoL, blood eosinophils, eosinophil cationic protein (ECP), skin prick test and serum total and specific immunoglobulin E (IgE) to major milk proteins were monitored before and after sterilised milk intake.ResultsEighteen patients (13 male...

Journal of Allergy and Clinical Immunology, 2009

Journal of Allergy and Clinical Immunology, 2010

World Allergy Organization Journal, 2007

United European gastroenterology journal, 2017

Eosinophilic esophagitis (EoE) is one of the most prevalent esophageal diseases and the leading c... more Eosinophilic esophagitis (EoE) is one of the most prevalent esophageal diseases and the leading cause of dysphagia and food impaction in children and young adults. This underlines the importance of optimizing diagnosys and treatment of the condition, especially after the increasing amount of knowledge on EoE recently published. Therefore, the UEG, EAACI ESPGHAN, and EUREOS deemed it necessary to update the current guidelines regarding conceptual and epidemiological aspects, diagnosis, and treatment of EoE. General methodology according to the Appraisal of Guidelines for Research and Evaluation (AGREE) II and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system was used in order to comply with current standards of evidence assessment in formulation of recommendations. An extensive literature search was conducted up to August 2015 and periodically updated. The working group consisted of gastroenterologists, allergists, pediatricians, otolaryngologists,...

Annals of Allergy, Asthma & Immunology, 2017

Journal of Allergy and Clinical Immunology, 2010

Journal of Allergy and Clinical Immunology, 2009

Digestive Diseases and Sciences

Journal of Allergy and Clinical Immunology, 2015

Pediatric Allergy and Immunology, 2015

ABSTRACT

Medicina Clinica, 2009

Background and objectives:To evaluate anti-IgE (ie, omalizumab) efficacy on severe allergic asthm... more Background and objectives:To evaluate anti-IgE (ie, omalizumab) efficacy on severe allergic asthma in order to achieve the efficacy of this treatment on severe allergic asthma progress by means of asthma control questionnaire (ACQ), asthma quality of life questionnaire (AQLQ) as well as pulmonary function (FEV1) and physician overall assessment.

Medicina Clínica, 2009

To evaluate anti-IgE (ie, omalizumab) efficacy on severe allergic asthma in order to achieve the ... more To evaluate anti-IgE (ie, omalizumab) efficacy on severe allergic asthma in order to achieve the efficacy of this treatment on severe allergic asthma progress by means of asthma control questionnaire (ACQ), asthma quality of life questionnaire (AQLQ) as well as pulmonary function (FEV1) and physician overall assessment. Fourteen patients were studied who suffered from severe allergic asthma for several years; average 20.7yr. A positive skin prick test or specific IgE antibodies to a common aeroallergen were observed in all patients who were under treatment with high doses of inhaled corticosteroids (eight of them also with oral corticosteroids). Omalizumab 150-600 mg were administrated once or twice monthly and each patient was monthly evaluated until sixteen weeks, deciding at this time which patient was or not responder in order to follow up or not omalizumab treatment. Physician overall assessment improved in 11 out of every 14 patients. A marked improvement was observed at two months in ACQ and AQLQ (p&amp;amp;amp;amp;amp;lt;0.05) and at 3 and 4 moths only in AQLQ and AQLQ-symptoms respectively (p&amp;amp;amp;amp;amp;lt;0.05). The FEV1 improved by 9.4% average (p=0.24). Oral corticosteroids were reduced in 4 of 8 patients and in another one there was a definitive suspension. Two patients suffered adverse reactions which suspension of treatment despite the fact that they presented improvement in questionnaires of quality of life and control of asthma. Omalizumab showed a marked global efficacy in more than 3 out of 4 patients suffering severe allergic asthma as revealed by physician overall assessment. Moreover significant improvements were observed in ACQ; AQLQ; AQLQ-symptoms at 2, 3 and 4 months of treatment, without significant changes in FEV1 probably due to chronic irreversible changes in airways.